<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01264575</url>
  </required_header>
  <id_info>
    <org_study_id>SMC-2010-12-18</org_study_id>
    <nct_id>NCT01264575</nct_id>
  </id_info>
  <brief_title>ED50 and ED95 of Intrathecal Bupivacaine With or Without Epinephrine for Total Knee Replacement Arthroplasty</brief_title>
  <official_title>ED50 and ED95 of Intrathecal Bupivacaine With or Without Epinephrine for Total Knee Replacement Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective randomized double-blind dose-response study is aimed to investigate the ED50
      and ED95 of intrathecal bupivacaine with or without epinephrine 100 mcg for total knee
      replacement arthroplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing total knee replacement arthroplasty are randomly assigned to six
      bupivacaine dose group (6, 7, 8, 9, 10, 11 mg). Combined spinal-epidural anesthesia would be
      performed. The dose would be considered as successful if no epidural supplement was required
      during surgery. A probit analysis will be performed to calculate the ED50 and ED95 of
      intrathecal bupivacaine with or without epinephrine for total knee replacement arthroplasty.

      After these measurements, ED50 and ED95 of bupivacaine with epinephrine would be compared
      with those without epinephrine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the success of anesthesia</measure>
    <time_frame>during the surgery (average two hours)</time_frame>
    <description>The individual dose would be considered to be successful if no epidural supplement is required during surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effects of the various intrathecal bupivacaine dose</measure>
    <time_frame>during surgery (average two hours)</time_frame>
    <description>lowest systolic blood pressure, vasopressure requirements, nausea, vomitting</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Spinal Anesthesia</condition>
  <condition>Total Knee Replacement Arthroplasty</condition>
  <arm_group>
    <arm_group_label>BPV6E1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BPV7E1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BPV8E1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BPV9E1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BPV10E1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BPV11E1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BPV6E2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BPV7E2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BPV8E2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BPV9E2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BPV10E2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BPV11E2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intrathecal bupivacaine 6 mg with 100 mcg of epinephrine</intervention_name>
    <description>intrathecal bupivacaine 6 mg with 100 mcg of epinephrine</description>
    <arm_group_label>BPV6E1</arm_group_label>
    <other_name>marcaine</other_name>
    <other_name>epinephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intrathecal bupivacaine 7 mg with 100 mcg of epinephrine</intervention_name>
    <description>intrathecal bupivacaine 7 mg with 100 mcg of epinephrine</description>
    <arm_group_label>BPV7E1</arm_group_label>
    <other_name>marcaine</other_name>
    <other_name>epinephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intrathecal bupivacaine 8 mg with 100 mcg of epinephrine</intervention_name>
    <description>intrathecal bupivacaine 8 mg with 100 mcg of epinephrine</description>
    <arm_group_label>BPV8E1</arm_group_label>
    <other_name>marcaine</other_name>
    <other_name>epinephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intrathecal bupivacaine 9 mg with 100 mcg of epinephrine</intervention_name>
    <description>intrathecal bupivacaine 9 mg with 100 mcg of epinephrine</description>
    <arm_group_label>BPV9E1</arm_group_label>
    <other_name>marcaine</other_name>
    <other_name>epinephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intrathecal bupivacaine 10 mg with 100 mcg of epinephrine</intervention_name>
    <description>intrathecal bupivacaine 10 mg with 100 mcg of epinephrine</description>
    <arm_group_label>BPV10E1</arm_group_label>
    <other_name>marcaine</other_name>
    <other_name>epinephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intrathecal bupivacaine 11 mg with epinephrine 100 mcg</intervention_name>
    <description>intrathecal bupivacaine 11 mg with epinephrine 100 mcg</description>
    <arm_group_label>BPV11E1</arm_group_label>
    <other_name>marcaine</other_name>
    <other_name>epinephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intrathecal bupivacaine 6 mg with 200 mcg of epinephrine</intervention_name>
    <description>intrathecal bupivacaine 6 mg with 200 mcg of epinephrine</description>
    <arm_group_label>BPV6E2</arm_group_label>
    <other_name>bupivacaine</other_name>
    <other_name>epinephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intrathecal bupivacaine 7 mg with 200 mcg of epinephrine</intervention_name>
    <description>intrathecal bupivacaine 7 mg with 200 mcg of epinephrine</description>
    <arm_group_label>BPV7E2</arm_group_label>
    <other_name>bupivacaine</other_name>
    <other_name>epinephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intrathecal bupivacaine 8 mg with 200 mcg of epinephrine</intervention_name>
    <description>intrathecal bupivacaine 8 mg with 200 mcg of epinephrine</description>
    <arm_group_label>BPV8E2</arm_group_label>
    <other_name>bupivacaine</other_name>
    <other_name>epinephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intrathecal bupivacaine 9 mg with 200 mcg of epinephrine</intervention_name>
    <description>intrathecal bupivacaine 9 mg with 200 mcg of epinephrine</description>
    <arm_group_label>BPV9E2</arm_group_label>
    <other_name>bupivacaine</other_name>
    <other_name>epinephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intrathecal bupivacaine 10 mg with 200 mcg of epinephrine</intervention_name>
    <description>intrathecal bupivacaine 10 mg with 200 mcg of epinephrine</description>
    <arm_group_label>BPV10E2</arm_group_label>
    <other_name>bupivacaine</other_name>
    <other_name>epinephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intrathecal bupivacaine 11 mg with 200 mcg of epinephrine</intervention_name>
    <description>intrathecal bupivacaine 11 mg with 200 mcg of epinephrine</description>
    <arm_group_label>BPV11E2</arm_group_label>
    <other_name>bupivacaine</other_name>
    <other_name>epinephrine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patients with ASA class I or II scheduled for total knee replacement surgery

        Exclusion Criteria:

          -  Patients with previous spine surgery, diabetic and other neuropathy, skin infection at
             the site of injection, allergy to bupivacaine and other common contraindications for
             spinal anesthesia were excluded from this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Ho Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-740</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2010</study_first_submitted>
  <study_first_submitted_qc>December 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2010</study_first_posted>
  <last_update_submitted>January 29, 2012</last_update_submitted>
  <last_update_submitted_qc>January 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul Medical Center</investigator_affiliation>
    <investigator_full_name>Won Ho Kim</investigator_full_name>
    <investigator_title>Staff Anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>spinal anesthesia</keyword>
  <keyword>intrathecal bupivacaine</keyword>
  <keyword>epinephrine</keyword>
  <keyword>ED50</keyword>
  <keyword>ED95</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

